The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 American Academy of Allergy, ...

Charlie Gayer led the commercial rollout of Orladeyo, which brought in $601 million last year and is expected to hit $1 billion by decade's end.

Sometimes, finding out how patients really feel about treatment takes persistence. That's what BioCryst Pharmaceuticals learned when it started talking to patients about its new oral preventive ...

BioCryst faces heightened competition in the HAE market due to Pharvaris' positive CHAPTER-1 study of deucrictibant. Despite strong Q3 2023 revenues, BioCryst's long-term debts cast a shadow over its ...

In just 72 words, BioCryst Pharmaceuticals announced it would pause enrollment for three phase 2 trials of its rare disease candidate BCX9930, sending shares tumbling 30%. The extremely brief ...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is one of the stocks Jim Cramer commented on. A caller asked if the current ...

Is this a merger out of weakness and necessity? Wall Street might think so. According to the early morning press release, the combined company will be led by Vincent Milano, the CEO of Idera, while ...

BioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter ...

BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a ...

Biotech stocks rebounded in 2025. Wedbush’s Laura Chico explains why rare disease catalysts and upcoming data could shape the ...